Publications by authors named "S Mazzotta"
Carnosine is a naturally occurring dipeptide that has been advocated by some authors as an interesting scaffold for the development of potential therapeutic agents in view of the positive outcomes of its supplementation in animal models of human diseases. Its mode of action seems to depend on the quenching of toxic electrophiles, such as 4-hydroxynonenal (HNE). However, carnosine's bioavailability in humans is lower than that in other mammals.
View Article and Find Full Text PDFArticle Synopsis
- Developing high-affinity monovalent ligands for lectins is difficult due to weak binding interactions, prompting research into covalent ligands for BC2L-C lectin, which is linked to severe respiratory infections in immunocompromised patients.
- Antiadhesion therapy is gaining traction as a strategy against infections, particularly targeting bacterial lectins like BC2L-C-Nt, which recognizes specific blood group oligosaccharides in host cells.
- Using computational methods, researchers created effective reversible covalent ligands that enhanced their binding affinity significantly, demonstrating the crucial role of specific ligand components in achieving this improved efficacy.
Atherosclerosis is a chronic vascular disease. Its prevalence increases with aging. However, atherosclerosis may also affect young subjects without significant exposure to the classical risk factors.
View Article and Find Full Text PDFNeurodegenerative diseases represent an increasingly burdensome challenge of the past decade, primarily driven by the global aging of the population. Ongoing efforts focus on implementing diverse strategies to mitigate the adverse effects of neurodegeneration, with the goal of decelerating the pathology progression. Notably, in recent years, it has emerged that the use of nanoparticles (NPs), particularly those obtained through green chemical processes, could constitute a promising therapeutic approach.
View Article and Find Full Text PDFThe mutational status of the IGHV gene is routinely assessed in patients with chronic lymphocytic leukaemia (CLL), since it is both prognostic of clinical outcome and predictive of response to treatment. This study evaluates the IGHV mutational status, assessed in newly diagnosed CLL patients, as a stand-alone predictor of time to first treatment (TTFT). We analysed the data of 236 CLL patients, diagnosed at our centre between January 2004 and September 2020, with a minimum follow-up period of 3.
View Article and Find Full Text PDF